BR112014018528A2 - - Google Patents
Info
- Publication number
- BR112014018528A2 BR112014018528A2 BR112014018528A BR112014018528A BR112014018528A2 BR 112014018528 A2 BR112014018528 A2 BR 112014018528A2 BR 112014018528 A BR112014018528 A BR 112014018528A BR 112014018528 A BR112014018528 A BR 112014018528A BR 112014018528 A2 BR112014018528 A2 BR 112014018528A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 | |
| PCT/US2013/029084 WO2013134243A1 (en) | 2012-03-07 | 2013-03-05 | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014018528A2 true BR112014018528A2 (https=) | 2017-06-20 |
| BR112014018528A8 BR112014018528A8 (pt) | 2017-07-11 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014018528A BR112014018528A8 (pt) | 2012-03-07 | 2013-03-05 | Derivados de pirido [2,3] pirimidina 2-amino, 6-fenil substituídos úteis como inibidores de raf quinase |
Country Status (39)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| CA3026876A1 (en) * | 2016-06-10 | 2017-12-14 | Novartis Ag | Therapeutic uses of a c-raf inhibitor |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| AU2018258581A1 (en) * | 2017-04-28 | 2019-11-07 | Quartz Therapeutics, Inc. | RAF-degrading conjugate compounds |
| HRP20230400T1 (hr) | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| BR112021012812A2 (pt) | 2018-12-28 | 2021-12-07 | Deciphera Pharmaceuticals Llc | Csf1r inhibitors para uso e tratamento de câncer |
| HRP20240012T1 (hr) | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori |
| AR118119A1 (es) * | 2019-02-18 | 2021-09-22 | Genentech Inc | Compuestos de pirido-pirimidinilo y métodos de uso |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| PE20221083A1 (es) | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US12064421B2 (en) | 2020-11-02 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| JP7849366B2 (ja) | 2020-12-22 | 2026-04-21 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｓｏｓ１阻害剤およびその使用 |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| JP2024542692A (ja) | 2021-12-01 | 2024-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物 |
| JP2024543976A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CN118574835A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| CA3240192A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| JP2025501744A (ja) | 2021-12-23 | 2025-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脳浸透性ｓｏｓ１阻害剤としての８－アザキナゾリン |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| JP2026512969A (ja) | 2022-10-26 | 2026-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇを活性化することができる複素環式化合物 |
| CA3266173A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024246099A1 (en) | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
| US20250206720A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Solid forms of an ulk inhibitor |
| WO2025122952A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| TW202542151A (zh) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250313560A1 (en) | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR |
| EP1566379A4 (en) * | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| UY33221A (es) * | 2010-02-09 | 2011-09-30 | Univ California | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en not_active Ceased
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en not_active Ceased
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 HK HK15103082.6A patent/HK1202541A1/xx unknown
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko not_active Abandoned
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/me unknown
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986A1/en unknown
-
2016
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |